Is Albert David a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Albert David Ltd is a good quality company .

Is Albert David undervalued or overvalued?

The key valuation ratios of Albert David Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Albert David share price return in the past 10 years?

Albert David Ltd share price has appreciated 16.5% annually (CAGR) over the past ten years.

Is Albert David a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Albert David Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

Albert David Ltd - Stock Valuation and Financial Performance

Name: Albert David
Brand: Albert David

BSE: 524075 | NSE: ALBERTDAVD | Pharmaceuticals & Drugs | Small Cap

Place order

Albert David Share Price

₹1,318.90 -33.35 -2.47%
as on 20-Dec'24 16:59

10 Year X-Ray of Albert David:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	18.2%	46.5%	14.3%	7.9%	20.6%	13.7%	12%	18.1%	17.1%	27.8%	-
Value Creation Index ⓘ	0.3	2.3	0.0	-0.4	0.5	0.0	-0.1	0.3	0.2	1.0	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	322	323	295	290	317	321	247	314	342	362	365
Sales YoY Gr.	-	0.3%	-8.5%	-1.7%	9.3%	1.1%	-22.9%	26.7%	9%	6.1%	-
Adj EPS ⓘ	23	33.3	23.7	11.4	26	36.4	37	57.1	62.9	130.3	120.1
YoY Gr.	-	44.5%	-28.8%	-52%	128.7%	39.8%	1.6%	54.4%	10.1%	107.2%	-
BVPS (₹) ⓘ	162.6	239.8	320.7	325.8	368.7	390.4	428.2	489.7	545.9	671.1	724.1
Adj Net Profit ⓘ	13.2	19	13.5	6.5	14.9	20.8	21.1	32.6	35.9	74.3	69
Cash Flow from Ops. ⓘ	27.8	68	19.9	30	31.9	30.3	36.6	40.4	10.5	45.5	-
Debt/CF from Ops. ⓘ	1.1	0.3	1.5	0.9	0	0.1	0	0.1	0.5	0.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	1.3%	2.7%	13.6%	6.1%
Adj EPS ⓘ	21.2%	38%	52.2%	107.2%
BVPSⓘ	17.1%	12.7%	16.2%	22.9%
Share Price	16.5%	27.3%	31.4%	37.1%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	14.4	16.6	8.5	3.5	7.5	9.6	9	12.4	12.1	21.4	17.2
Op. Profit Mgn % ⓘ	11.5	9.7	6.6	5.9	9.4	10.6	7.8	13.1	13.2	13	6.9
Net Profit Mgn % ⓘ	4.1	5.9	4.6	2.2	4.7	6.5	8.5	10.4	10.5	20.5	18.8
Debt to Equity ⓘ	0.3	0.2	0.2	0.2	0	0	0	0	0	0	0
Working Cap Days ⓘ	174	161	194	212	193	190	227	183	201	201	189
Cash Conv. Cycle ⓘ	60	62	62	47	32	28	36	27	32	31	141

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 17.20%

Sales growth is growing at healthy rate in last 3 years 13.57%

Net Profit is growing at healthy rate in last 3 years 52.16%

Sales growth is not so good in last 4 quarters at 7.65%

Latest Financials - Albert David Ltd.

	Standalone	Consolidated
TTM EPS (₹)	120.1	-
TTM Sales (₹ Cr.)	365	-
BVPS (₹.) ⓘ	724.1	-
Reserves (₹ Cr.) ⓘ	414	-
P/BV ⓘ	1.82	-
PE ⓘ	10.98	-

From the Market
52 Week Low / High (₹)	924.05 / 1752.95
All Time Low / High (₹)	3.15 / 1752.95
Market Cap (₹ Cr.)	753
Equity (₹ Cr.)	5.7
Face Value (₹)	10
Industry PE ⓘ	44.3

Management X-Ray of Albert David:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Albert David

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Albert David

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	322	323	295	290	317	321	247	314	342	362
Operating Expenses ⓘ	285	291	277	275	288	290	228	273	297	315
Manufacturing Costs	76	66	54	56	55	54	33	50	65	62
Material Costs	64	60	56	60	75	74	70	87	87	91
Employee Cost	75	82	83	86	90	90	83	85	81	88
Other Costs ⓘ	69	84	84	73	68	72	43	50	64	74
Operating Profit ⓘ	37	31	18	16	29	31	19	41	44	47
Operating Profit Margin (%)	11.5%	9.7%	6.1%	5.4%	9.2%	9.5%	7.8%	13.1%	13.0%	13.0%
Other Income ⓘ	2	2	16	10	21	7	17	16	15	58
Interest ⓘ	3	2	1	1	1	1	1	1	1	0
Depreciation ⓘ	15	9	8	8	7	8	8	9	9	7
Exceptional Items ⓘ	0	41	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	20	63	26	16	43	29	27	47	51	97
Tax ⓘ	7	15	10	6	16	10	5	12	15	22
Profit After Tax	14	48	16	10	27	19	22	35	36	75
PAT Margin (%)	4.3%	14.9%	5.4%	3.4%	8.4%	6.0%	8.9%	11.2%	10.6%	20.8%
Adjusted EPS (₹)	24.0	84.1	28.0	17.2	46.7	33.6	38.8	61.8	63.4	132.2
Dividend Payout Ratio (%)	23%	7%	20%	32%	13%	21%	15%	15%	14%	9%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	93	137	183	186	210	223	244	279	312	383
Share Capital ⓘ	6	6	6	6	6	6	6	6	6	6
Reserves ⓘ	87	131	177	180	205	217	239	274	306	377
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	28	20	30	28	0	1	1	4	4	2
Long Term Debt	6	0	0	0	0	1	0	0	0	0
Short Term Debt	22	20	30	28	0	0	0	4	4	2
Trade Payables	31	27	27	32	30	38	25	30	32	34
Others Liabilities ⓘ	80	81	110	116	135	136	135	161	165	185
Total Liabilities ⓘ	231	265	351	361	376	398	405	475	512	604
Fixed Assets
Gross Block	168	172	221	192	192	212	212	223	222	231
Accumulated Depreciation	118	127	134	109	115	121	128	135	142	148
Net Fixed Assetsⓘ	49	44	87	83	77	91	84	88	80	83
CWIP ⓘ	5	5	9	5	5	2	1	1	3	7
Investmentsⓘ	17	48	59	68	113	122	138	183	193	273
Inventories	52	49	51	43	44	43	36	39	51	44
Trade Receivables	41	35	33	27	22	30	19	25	30	29
Cash Equivalents	10	23	15	26	7	7	35	19	25	31
Others Assetsⓘ	57	60	98	109	108	104	92	121	131	137
Total Assets ⓘ	231	265	351	361	376	398	405	475	512	604

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	28	68	20	30	32	30	37	40	11	46
PBT ⓘ	20	22	26	16	43	29	27	47	51	97
Adjustment ⓘ	18	63	2	3	-13	7	-7	-6	1	-44
Changes in Working Capital ⓘ	-3	10	3	19	8	9	19	11	-26	9
Tax Paid ⓘ	-7	-27	-11	-7	-6	-15	-2	-13	-16	-16
Cash Flow From Investing Activity ⓘ	-9	-38	-37	-11	-19	-20	-39	-40	-5	-33
Capex	-9	-6	-20	1	14	-15	-1	-9	-5	-11
Net Investments	0	-32	-9	-6	-39	-9	-40	-42	1	-33
Others ⓘ	0	0	-8	-6	7	4	3	11	-1	11
Cash Flow From Financing Activityⓘ	-18	-18	7	-5	-17	-10	-2	-2	-6	-8
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-16	-8	0	0	0	-1	-1	0	0	0
Interest Paid ⓘ	-3	-2	-1	0	0	-1	0	0	0	0
Dividend Paid ⓘ	-3	-6	-1	-4	-4	-9	0	-3	-5	-5
Others ⓘ	4	-2	8	0	-13	0	0	2	-1	-3
Net Cash Flow ⓘ	1	12	-10	14	-4	0	-4	-1	-1	4

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	14.96	41.8	9.98	5.33	13.44	8.85	9.48	13.46	12.24	21.72
ROCE (%)	18.22	46.48	14.29	7.94	20.6	13.74	11.99	18.1	17.1	27.84
Asset Turnover Ratio	1.35	1.35	1	0.87	0.9	0.87	0.65	0.75	0.73	0.69
PAT to CFO Conversion(x)	2	1.42	1.25	3	1.19	1.58	1.68	1.14	0.31	0.61
Working Capital Days
Receivable Days	46	42	41	36	27	28	35	25	28	28
Inventory Days	52	55	59	55	48	47	55	41	45	45
Payable Days	160	157	166	181	149	167	165	115	131	133

Albert David Ltd Stock News

Albert David Ltd FAQs

What is the share price of Albert David?

Company share prices are keep on changing according to the market conditions. The closing price of Albert David on 20-Dec-2024 16:59 is ₹1,318.9.

What is the market cap of Albert David?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Albert David stood at ₹752.7.

What is the P/E ratio of Albert David?

The latest P/E ratio of Albert David as of 20-Dec-2024 16:59 is 10.98.

What is the P/B ratio of Albert David?

The latest P/B ratio of Albert David as of 20-Dec-2024 16:59 is 1.82.

What is the 52-week high and low of Albert David?

The 52-week high of Albert David is ₹1,753 and the 52-week low is ₹924.0.

What is the TTM revenue of Albert David?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Albert David is ₹365.1 ( Cr.) .

About Albert David Ltd

Albert David was incorporated in the year 1938. The company is a part of Kothari group.

Albert David, which has decades of illustrious presence in the health care industry, manufactures pharmaceutical formulations and bulk drugs, infusion solutions and oral solids, disposable syringes and needles and herbal formulations. The company exports these products to Vietnam, Russia, Belarus, Egypt, Bangladesh, Kenya, Tanzania, Uganda, Sudan, Ethiopia, Nigeria, Zaire, Haiti, Brazil, Canada, USA, UK, Netherlands and Germany as the company is a WHO-approved supplier.

It also has DMF for the bulk drugs, Tolbutamide and Chlorpropamide with the US Food and Drugs Administration (USFDA). The manufacturing facility for these products has been inspected and validated by the US drug regulator.

The manufacturing plants of the company are located at Ghaziabad near New Delhi, Kolkata and Mandideep near Bhopal.

The company`s amino acid range under the brand name of Alamin contains pure crystalline amino acid of high international standards manufactured under a unique technology, which conforms to WHO and FAO recommendations. In the herbal segment, the company sells its products under brand names like Adliv, which is a hepato protective and Siotone capsule, which is the only adaptogen indicated for stress.

ADL has tie-ups with Ajinomoto Co and Roussel Morishita Co of Japan for manufacturing and marketing a wide range of crystalline amino acid infusion solutions, oral solids and liquids in India.

Products offered by the Company:

The company is operating in major therapeutic segments that include:

Analgesics/AntiInflammatory
Anti-Bacterials
Anti-Ulcerants
Dermatologicals
Anxiolytics
Large Volume Parenteral
Disposable Syringes & Needles
Herbal Drugs
Nutrition
Neurotropics
Placental Extracts
Anthelmintic
Haemostati
Cough Preparations
Laxatives
Skeletal Relaxants
Anti-Arthiritic / Chondroprotective Agents.

Future Plans:

The company will explore the possibilities for export of its IV fluids, small volume parenterals and disposable syringes in addition to its existing range.
It will concentrate on product line extension for its flagship brand Placentrex by bringing in newer formulations and looking for a new therapeutic area of usage.
Future expansion in the herbal product range will be focused in the area of women`s healthcare.
ADL is planning to enter newer therapeutic areas like dermatological and ophthalmological segments.
Furthermore, it will also strengthen its presence in the gastrointestinal segments and in the areas of pain management.
The company is also planning to launch newer products in the areas of nutritional, gynaecological and herbal medicine.